Jade Biosciences, Inc. - Asset Resilience Ratio
Jade Biosciences, Inc. (JBIO) has an Asset Resilience Ratio of 80.21% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See JBIO FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Jade Biosciences, Inc.'s Asset Resilience Ratio has changed over time. See JBIO net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Jade Biosciences, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see JBIO stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $256.21 Million | 80.21% |
| Total Liquid Assets | $256.21 Million | 80.21% |
Asset Resilience Insights
- Very High Liquidity: Jade Biosciences, Inc. maintains exceptional liquid asset reserves at 80.21% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jade Biosciences, Inc. Industry Peers by Asset Resilience Ratio
Compare Jade Biosciences, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Jade Biosciences, Inc. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Jade Biosciences, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.82% | $247.72 Million | $349.78 Million | +14.96pp |
| 2024-12-31 | 55.86% | $44.87 Million | $80.33 Million | -21.80pp |
| 2023-12-31 | 77.66% | $98.95 Million | $127.42 Million | -1.30pp |
| 2022-12-31 | 78.95% | $106.82 Million | $135.30 Million | +14.41pp |
| 2021-12-31 | 64.54% | $113.18 Million | $175.36 Million | -- |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more